Iressa for Elderly and/or Poor Performance Status Patients with an EGFR Mutation Article Several years ago, we learned that EGFR tyrosine kinase inhibitors (TKIs) were not a very helpful strategy for an unselected population of frail patients in the US, clearly inferior to standard chemotherapy (see prior posts here and here). Read more about Iressa for Elderly and/or Poor Performance Status Patients with an EGFR Mutation4 comments